The shortcomings of animal disease models are well known. More than 90% of drugs fail in early human testing because safety and efficacy results from animal tests do not always predict drug performance in humans. Sometimes this results in fatalities. New technologies like AI and “organs on a chip,” using healthy and patient-derived induced pluripotent stem cells to create ready-to-use assay plates containing living microtissues, could soon redefine the preclinical landscape by significantly reducing the need for animal testing. Not only would this prevent the needless suffering of countless lab animals, but it also offers the promise of improving the accuracy and efficiency of early drug development. This panel will explore how these highly scalable new technologies could deliver significant cost and time savings to the pharmaceutical industry, end animal testing, and potentially lead to safer, more consistent and accurate human clinical trials.